The USFDA has approved Sernivo Spray (Betamethasone dipropionate), a topical corticosteroid for treatment of mild to moderate plaque psoriasis. The drug is to be manufactured by Promius Pharma LLC.
Two double-blinded, randomized, controlled studies were conducted to demonstrate the safety and efficacy of Sernivo Spray. The subjects were randomized to receive Sernivo Spray or a placebo spray, twice daily for 28 days. At 29th day, about 42.7% and 34.5% of patients have achieved treatment success, compared to 11.7% and 13.6% in placebo group.
Some of the reported common adverse events were atrophy at the application site, pruritus, pain and burning or stinging sensation.
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.